Clinical Trial Update: Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety update for Renzapride in women with constipation-predominant irritable bowel syndrome; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Renzapride (renzapride)

Snippet

Sponsor: Alizyme | Conditions: Constipation-Predominant Irritable Bowel Syndrome | Phase 3 | Status: TERMINATED